Abstract
Dietary sulfur amino acid restriction (SAAR) improves metabolic health in animals, but in humans, SAAR has not been investigated in translational clinical trials. In this study, we investigated the effect of dietary SAAR on body weight, body composition, resting metabolic rate, gene expression profiles in white adipose tissue (WAT), and an extensive blood biomarker profile in 59 humans with overweight and obesity in a double-blind, randomized controlled trial (ClinicalTrials.gov: NCT04701346). Participants were randomized to a plant-based diet low (∼2 g/d, SAAR) or high (∼5.6 g/d, control group) in sulfur amino acids. The diets were provided in full to the participants. After 8 weeks of intervention, SAAR led to a ∼20 % greater weight loss compared to controls (β (95 % CI) -1.14 (-2.04, -0.25) kg, p = 0.012). Despite greater weight loss, resting metabolic rate remained similar between groups. Furthermore, SAAR decreased serum leptin, and increased ketone bodies compared to controls. In WAT, 20 genes were upregulated whereas 24 genes were downregulated (FDR < 5 %) in the SAAR group compared to controls. Generally applicable gene set enrichment analyses revealed that processes associated with ribosomes were upregulated, whereas processer related to structural components were downregulated. In conclusion, our study shows that SAAR leads to weight loss and metabolic benefits. Further research SAAR is needed to investigate the therapeutic potential for metabolic conditions in humans.
Competing Interest Statement
The authors have declared no competing interest.
Clinical Trial
NCT04701346
Clinical Protocols
https://translational-medicine.biomedcentral.com/articles/10.1186/s12967-021-02824-3
Funding Statement
This project has received funding from The Research Council of Norway (Grant no: 310475) under the umbrella of the European Joint Programming Initiative A Healthy Diet for a Healthy Life (JPI HDHL) and of the ERA-NET Cofund HDHL INTIMIC (Grant number 727565 of the EU Horizon 2020 Research and Innovation Programme), and Institute of Basic Medical Sciences, University of Oslo, and Henning och Johan Throne-Holsts stiftelse.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The Regional Ethical Committee South-East, Norway, gave ethical approval for this work (Ref no. 123644).
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Footnotes
↵a Shared authorship.
6. Data availability
Raw data from this study cannot be made publicly available due to existing European privacy regulations. Requests for data can be made to the corresponding author and will be shared pending approved protocols by relevant ethical committees and privacy regulation authorities.
